EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Allosteric and ATP-Pocket BCR::ABL1 Inhibition In Vitro, and Characterising Ex Vivo Thrombo-Inflammatory Biomarkers and Thrombin Generation in Asciminib-Treated CML Patients

Musab M A Omar, Majed A Alanazi, David T Yeung, Timothy P Hughes, Denise E Jackson iD

International Journal of Molecular Sciences · 18.04.2026 · 27 (8) · 3623

DOI: 10.3390/ijms27083623 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 18.04.2026. Verfasst von Musab M A Omar und 4 weiteren Autor:innen. Beteiligte Einrichtung: Thrombosis and Vascular Diseases Laboratory, School of Health and Biomedical Sciences, STEM College, RMIT University, Melbourne, VIC 3000, Australia. Hauptthemen laut MEDLINE: Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Thrombin, Fusion Proteins, bcr-abl, Protein Kinase Inhibitors. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic myeloid leukaemia (CML) is driven by the t(9;22) forming the BCR::ABL1 fusion gene, leading to the development of hyper-myeloid proliferation. This led to development of tyrosine kinase inhibitors (TKIs) such as Imatinib, Nilotinib, and Ponatinib. However, resistance or intolerance to ATP-competitive TKIs remains a challenge for some patients. asciminib (ABL001), a novel TKI, targets the myristoyl pocket of ABL1 instead of the ATP-binding site, reducing resistance to mutations. As asciminib is linked to thrombocytopenia, its effects on platelet activation, endothelial function, and inflammation must be studied to assess its potential to promote thrombosis. The main objective of this study is to determine the potential of asciminib as a monotherapy in inducing pathological responses to platelets and endothelium over time within the vasculature. This study assessed the effects of TKIs including asciminib on platelets and thrombotic biomarkers. Washed platelets were used to measure granule secretion, thrombus formation, surface expression of glycoproteins, apoptosis, and viability. Plasma from chronically Asciminib-treated CML patients was analysed using sandwich ELISA for inflammatory and platelet–endothelial biomarkers, and thrombin generation assays were performed to study coagulation. This approach combined in vitro and ex vivo methods to explore the impact of asciminib on platelet function and thrombotic potential. The study shows that acute treatment with asciminib does not promote platelet activation or thrombus formation. Instead, it exhibits an inhibitory effect on thrombus formation in vitro and is associated with reduced thrombo-inflammatory biomarkers ex vivo in chronically treated CML patients. Asciminib was associated with increased thrombin generation over time, suggesting an effect on secondary haemostasis. Asciminib does not appear to induce a prothrombotic or proinflammatory state under the conditions studied, which may be advantageous for CML patients. However, the observed increase in thrombin generation over time suggests a potential effect on secondary haemostasis that warrants further investigation in controlled studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myelogenous, Chronic, BCR-ABL PositiveThrombinFusion Proteins, bcr-ablProtein Kinase InhibitorsHumansBlood PlateletsMaleThrombosisFemaleBiomarkersInflammationAdenosine TriphosphatePlatelet ActivationMiddle AgedTyrosine Kinase InhibitorsAllosteric RegulationAdult

Stichwörter der Autor:innen

CMLhaemostasisinflammationplateletsthrombosis

Substanzen

ThrombinFusion Proteins, bcr-ablProtein Kinase InhibitorsBiomarkersAdenosine TriphosphateBCR-ABL1 fusion protein, humanTyrosine Kinase Inhibitors

Autor:innen und Institutionen

  • Thrombosis and Vascular Diseases Laboratory, School of Health and Biomedical Sciences, STEM College, RMIT University, Melbourne, VIC 3000, Australia.
  • Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Taibah University, Madinah 42353, Saudi Arabia.
  • Ministry of Education, Riyadh 12435, Saudi Arabia.
  • Haematology, SA Pathology, Adelaide, SA 5000, Australia.
  • Precision Cancer Medicine Theme, South Australian Health & Medical Research Institute, Adelaide, SA 5000, Australia.
  • School of Medicine, University of Adelaide, Adelaide, SA 5005, Australia.

ORCID-Profile: Denise E Jackson

Zitieren

APA

Omar, M. M. A., Alanazi, M. A., Yeung, D. T., Hughes, T. P., & Jackson, D. E. (2026). Allosteric and ATP-Pocket BCR::ABL1 Inhibition In Vitro, and Characterising Ex Vivo Thrombo-Inflammatory Biomarkers and Thrombin Generation in Asciminib-Treated CML Patients. International Journal of Molecular Sciences, 27(8), 3623. https://doi.org/10.3390/ijms27083623

Vancouver

Omar MMA, Alanazi MA, Yeung DT, Hughes TP, Jackson DE. Allosteric and ATP-Pocket BCR::ABL1 Inhibition In Vitro, and Characterising Ex Vivo Thrombo-Inflammatory Biomarkers and Thrombin Generation in Asciminib-Treated CML Patients. International Journal of Molecular Sciences. 2026;27(8):3623. doi:10.3390/ijms27083623

BibTeX
@article{Omar2026,
  author = {Omar, Musab M A and Alanazi, Majed A and Yeung, David T and Hughes, Timothy P and Jackson, Denise E},
  title = {Allosteric and ATP-Pocket BCR::ABL1 Inhibition In Vitro, and Characterising Ex Vivo Thrombo-Inflammatory Biomarkers and Thrombin Generation in Asciminib-Treated CML Patients},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {8},
  pages = {3623},
  doi = {10.3390/ijms27083623}
}
Kostenlos starten →